Armbruster Shannon, Coleman Robert L, Rauh-Hain Jose Alejandro
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030-1362, USA.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030-1362, USA; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1444, P.O. Box 301402, Houston, TX 77230-1402, USA.
Hematol Oncol Clin North Am. 2018 Dec;32(6):965-982. doi: 10.1016/j.hoc.2018.07.005.
Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The role of secondary cytoreduction remains a topic of active investigation.
大多数晚期上皮性卵巢癌女性会经历多次疾病复发，且无病间期逐渐缩短。对于疾病仍对铂类药物有反应的女性，疾病通常可得到5年或更长时间的控制。在这种疾病的治疗方面已经取得了巨大进展，抗血管生成药物、聚（腺苷二磷酸 - 核糖）聚合酶抑制剂和免疫检查点抑制剂等新的靶向治疗方法为提高生存率带来了潜力。正在评估各种联合策略以利用这些药物。二次细胞减灭术的作用仍然是一个积极研究的课题。
